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ABSTRACT

EVALUATION AND DETERMINATION OF THE SENSITIVITY AND
SPECIFICITY OF A Treponema pallidum DRIED BLOOD SPOT (DBS) METHOD
FOR SEROLOGIC DIAGNOSIS OF SYPHILIS
Background: Syphilis is a sexually transmitted infection (STI) caused by Treponema
pallidum subspecies pallidum. Syphilis is known as the “great imitator" due to the
similarity of clinical signs and symptoms to other infectious diseases. The primary
diagnosis of syphilis relies on clinical findings, including the examination of treponemal
lesions, and/or serologic tests. Serologic tests are divided into nontreponemal and
treponemal tests. Nontreponemal tests are useful for screening, while treponemal tests are
used as confirmatory tests.
Methods: A total of 200 serum and DBS specimens collected from patients at the Los Angeles
Municipal Sexually Transmitted Disease Clinics were tested by the DBS and enzyme
immunoassay (EIA) methods. These samples were sent to the Syphilis Diagnostics

Laboratory, Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia for
testing. Samples were blindly evaluated by the TREP-SPOTTM DBS and the TREPSURETM EIA methods for the detection of anti-treponemal IgG- and IgM-class
antibodies.
Results: The sensitivity of the DBS method was 83% (95% CI, 73.89 - 89.50) and specificity
was 100% (95% CI, 95.39 - 100)). The positive predictive value and negative predictive values
were 100% (95% CI, 94.48 - 100) and 85% (95% CI, 77.43 - 91.0), respectively. The efficiency
of the DBS method was 91.5%. The kappa value for the agreement between the DBS method and
EIA assay was 0.83 (95% CI, 0.754 - 0.906). The correlation coefficient (r 2) between the antitreponemal antibody assay results obtained from DBS and serum samples was 0.94.
Conclusion: DBS is an optimal choice to be used as a screening tool for the detection of

anti-treponemal antibodies for the diagnosis of syphilis. The detection of anti-treponemal
antibodies (TREP-SPOTTM DBS EIA) compared favorably to the results of serum-base
assay (TREP-SURETM EIA), with an overall concordance of 91.5%. Dried blood spots
are technically easier to obtain and are suitable blood samples for primary health care
centers.
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CHAPTER 1

INTRODUCTION

1.1

Background
Syphilis is a sexually transmitted infection (STI) caused by Treponema pallidum

subspecies pallidum. Syphilis is known as the “great imitator” due to its similarity of
clinical signs and symptoms to other infectious diseases. The World Health Organization
(WHO) reports that more than 340 million new cases of STI occur worldwide (WHO,
2012b) . Globally, STIs are a major public health burden in developing countries. STIs
account for one-third of the global burden of disease among women of reproductive age
(WHO, 2012b). According to Centers for Disease Control and Prevention (CDC), there
were over 36,000 documented cases of syphilis in 2006, including 9,756 cases of primary
and secondary syphilis (CDC, 2010). The incidence of primary and secondary syphilis is
highest in women 20 to 24 years of age and in men 35 to 39 years of age (CDC, 2012a).
The prevalence of congenital syphilis in newborns also increased from 2005 to 2006,
with 339 new cases reported in 2005, compared to 349 cases in 2006 (CDC, 2012a). The
cases of syphilis among men who have sex with men (MSM) showed the largest
increases since 2000 (CDC 2012a). MSM accounted for almost 62% of syphilis cases in
2009, up from 7% in 2000. CDC reported that the primary and secondary syphilis cases
increased from 13,500 in 2008 to 13,997 in 2009, an increase of 3.7% (CDC 2012a;
CDC, 2012b ). The rate of the primary and secondary syphilis was highest among
persons aged 20 to 24 years and 25 to 29 years in 2009 (CDC, 2012a ).
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The primary diagnosis of syphilis relies on clinical findings, including the
examination of treponemal lesions, and/or serologic tests. Serologic tests are classified
into two categories: nontreponemal and treponemal assays. Nontreponemal tests are
useful for screening, while treponemal tests are used as confirmatory tests.
Nontreponemal tests detect the host’s antibody response to nontreponemal (cardiolipinlecithin) antigen. Nontreponemal tests include the Venereal Disease Research Laboratory
(VDRL), the rapid plasma reagin (RPR), the toludine red unheated serum (TRUS), and
unheated serum reagin (USR) tests (Owusu-Eduse, 2011). In contrast, all treponemal
tests allow for the detection of specific treponemal antibodies. Serologic treponemal tests
include the microhemagglutination assay for T. pallidum (MHA-TP), T. pallidum particle
agglutination (TPPA), T. pallidum hemagglutination assay (TPHA), fluorescent
treponemal antibody absorption (FTA-ABS) test, and enzyme-linked immunosorbent
assay (ELISA) (Wong, 2011). More recently, rapid and reliable nucleic acid
amplification methods are available for the detection of T. pallidum in clinical samples
(Heymans, 2010). These methods added great value for the diagnosis of congenital
syphilis, neurosyphilis and early primary syphilis (Heymans, 2010).
Serum is the specimen of choice for both nontreponemal and treponemal
serologic tests even though plasma can be used in some nontreponemal tests. Dried
blood spots (DBS) have been used for rapid diagnosis of human immunodeficiency virus1(Rottinghaus, 2012) and newborn screening for phenylketonuria (De Silva, 2010).
Sample collection of DBS has never been routinely used for serologic confirmation of
syphilis.
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1.2

Purpose of Study
The aim of this study is to evaluate and determine the sensitivity and specificity of

a T. pallidum DBS method for serologic diagnosis of syphilis. For the purpose of this
study, TREP-SURETM EIA (Phoenix Bio-Tech Corporation, 2010) was used for the in
vitro diagnostic detection and confirmation of antitreponemal antibodies using a T.
pallidum TREP-SPOTTM DBS method (Phoenix Airmid Biomedical Corporation, 2012).

1.3

Research Questions
This thesis will focus on the following questions: 1) Does a T. pallidum DBS

method provide the sensitivity and specificity for the diagnosis and confirmation of
syphilis? 2) Can a T. pallidum DBS method be used for the diagnosis and confirmation of
syphilis? 3) Does a T. pallidum DBS method offer a convenient way to collect and
transport blood samples for the diagnosis and confirmation of syphilis?
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CHAPTER II

REVIEW OF THE LITERATURE

The purpose of this study is to evaluate and determine the sensitivity and
specificity of a T. pallidum DBS method for serologic diagnosis of syphilis. This
literature review will focus on the following major aspects: the global burden of STIs and
syphilis, etiology, epidemiology, pathogenesis, clinical signs and symptoms, laboratory
diagnosis of syphilis, and prevention and control.

2.1

Global burden of sexually transmitted infections
STIs are one of the leading causes of acute illness, long-term disability and death.

Globally, STIs still remain a major public health threat in both developed and developing
countries. According to the World Health Organization (WHO), over 340 million new
cases of STIs reported worldwide in 1999 (WHO, 2012a). The highest incidence of STIs
per 1000 population has occurred in sub-Saharan Africa (WHO, 2012a).
An estimated 12.22 million cases of syphilis occurred worldwide in 1999
according to WHO (WHO, 2012b). In contrast to Western Europe, the newly independent
states of the former Soviet Union reported an alarming increase in the rates in syphilis
(WHO, 2001). Syphilis incidence increased from 5 to 15 per 100,000 observed in 1990 to
as high as 120 to 170 per 100,000 population in 1996 in these countries (WHO, 2001).
The highest prevalence rate in pregnant women was 3.2% in Djibouti, followed by 3.0%
in Morocco, and 1.1% in Qatar (WHO, 2001). CDC estimated that the number of cases
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of primary and secondary syphilis in U.S. increased from 5,979 to 7,980; the rate
increased from 2.1 to 2.7 cases per 100,000 population from 2000 to 2004 (MMWR,
2006).
STIs are caused by bacterial, parasitic, or viral pathogens. Some of the more
common pathogens are Chlamydia trachomatis, Hemophilus ducreyi, Neisseria
gonorrhea, Treponema pallidum, Trichomonas vaginalis, herpes simplex virus 2, human
papillomavirus, hepatitis B virus, and human immunodeficiency virus (Ratnam, 2005).

2.2

Etiology and transmission of disease
Schaudinn and Hoffmann first identified T. pallidum as the causative agent for

syphilis in 1905 (de Souza, 2005). More importantly, Schaudinn named this organism by
using the Greek word trepo (I turn) and nema (thread) with the Latin word pallida (pale).
Treponema pallidum means “a pale turning thread” (de Souza, 2005). The causative
agent of syphilis is Treponema pallidum subspecies pallidum. T. pallidum is a member of
the order Spirochaetales, family Spirochaetaceae, and genus Treponemae. The other
three species of the genus Treponema cause diseases in humans. These include T.
pallidum subspecies pertenue, causing yaws; T. pallidum subspecies endemicum, causing
nonvenereal treponematosis (bejel); and T. carateum, causing pinta. Morphologically, T.
pallidum is a small, unicellular, tightly coiled and helical organism measuring 6 - 15 µm
in length and 14 - 0.2 µm in width (CDC, 2009a, 2009b). T. pallidum has not been
grown successfully on artificial culture media. However, the organism has been
cultivated in rabbit testicles (Brown, 1920).
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Syphilis is transmitted primarily through sexual contact. The disease may be
transmitted from mother to fetus during pregnancy or at birth resulting in congenital
syphilis. Syphilis can occur through blood transfusion from the donor in early stages of
infection (Gupta, 2012). Health care providers may acquire the primary lesions on the
hands after examining unprotected clinical lesions of syphilis.

T. pallidum only infects humans. Humans are the only known natural reservoir for
syphilis. The organism does not have a reservoir in animals or the environment (LaFond,
2006). The incubation period for syphilis is 10 days to 3 months. The average incubation
period of primary syphilis is usually about 3 weeks. However, symptoms can appear as
early as 9 days or as long as 3 months after exposure in rectal infections associated with
homosexual men (LaFond, 2006).

2.3

Epidemiology of syphilis
STIs are the leading cause of morbidity and mortality among men, women and

children (CDC, 2009). STIs still remain a major public health problem worldwide,
especially in developing countries. Globally, about 340 million preventable new cases
occur every year (WHO, 2001). Syphilis accounts for an estimated 12 million cases; 2
million of them are pregnant women (WHO, 2001). The 2000 Global Burden of Disease
Estimates reported that 1.3% of deaths among children under the age of 5 years were due
to congenital syphilis (WHO, 2001). The annual global number of cases of congenital
syphilis is estimated to be between 575,000 and 713,600 (Hossain, 2007). The newborn
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infants have a higher incidence of congenital syphilis than other infections caused by
human immunodeficiency virus-1 and Clostridium botulism (Rodríguez-Cerdeira, 2012).
The total number of primary, secondary, early latent, late, late latent and
congenital syphilis cases was 44,828 in 2009 in the United States according to CDC
(CDC, 2010). During 2008 to 2009, primary and secondary syphilis rates increased 10%
in the South, 2.7% in the Northeast, and 7.7% in the Midwest (CDC, 2010). In 2009,
syphilis rates were highest in the South, 6.6 cases per 100,000 population (CDC, 2010).
According to CDC in 2009, Louisiana, Georgia, Arkansas, Alabama, Mississippi,
Texas, Tennessee, North Carolina, New York, Illinois, Florida, Maryland, and California
reported the highest rates of primary and secondary syphilis (CDC, 2010). These 13
states accounted for 75% of all U.S. cases of primary and secondary syphilis and exceed
the national rate of 4.6 cases per 100,000 population (CDC, 2010). Of the 13 states with
the highest rates of primary and secondary syphilis, 10 states were in the South (CDC,
2010).

During 2008 to 2009, the number of primary and secondary syphilis infections in
men increased from 7.5 to 7.8 cases per 100,000 men, and decreased from 1.5 to 1.4
cases per 100,000 women during the same period (CDC 2009). In 2009, the overall rate
of reported primary and secondary syphilis was highest in people aged 20 to 24 years and
25 to 29 years, 11.3 cases per 100,00 population, respectively (CDC, 2010). From 2008
to 2009, the reported incidence of primary and secondary syphilis increased in all ethnic
groups except non-Hispanic whites and Hispanics. The rate of primary and secondary
syphilis in non-Hispanics increased by 11.6% (from 17.2 cases per 100,000 population),
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6.7% in Asian/Pacific Islanders (from 1.5 to 1.6 cases per 100,000 population), and 4.3%
in American Indians/Alaska Natives (from 2.3% to 2.4 cases per 100,000) (CDC, 2009a).
From 2008 to 2009, the incidence of primary and secondary syphilis decreased in nonHispanic Whites and Hispanics, with a 4.5% decrease in non-Hispanic whites (from 2.2
to 2.1 per 100,000 population) and 2.2% in Hispanics (from 4.6 to 4.5 cases per 100,000
population) (CDC, 2009a).

2.4

Pathogenesis, clinical signs and symptoms
Syphilis remains a significant public health challenge. Mechanisms of T. pallidum

pathogenesis are poorly understood for three reasons: 1) the inability to cultivate the
causative agent in vitro; 2) the lack of suitable animal models; 3) the limited availability
of information from human studies. Because of the paucity of human studies, the
postulated pathogenesis of syphilis is primarily derived from animal models. Some early
animal studies offered important insight into syphilis pathogenesis (Cameron, 1998). T.
pallidum enters the body via skin and mucous membranes through small abrasions during
sexual contact. Magnuson et al. (Magnuson, 1948) demonstrated a darkfield positive
lesion when two organisms of T. pallidum were intracutaneously inoculated in rabbits.
After initial entry, symptoms appear, within a few hours after inoculation, as T. pallidum
navigates the lymphatic system and regional lymph nodes before traveling throughout the
body via the blood stream (Singh, 1999). In some cases, the organism may remain at the
site of entry, multiplying and sensitizing lymphocytes, while activating macrophages,
resulting in the chancre at the site of transmission. Although the exact mechanism by
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which T. pallidum enters the host cell has not been completely elucidated, it is most
likely T. pallidum attaches to host cells by specific attachment ligands. It appears that
penetration and damage of endothelial cells is critical for the pathogenicity and virulence
of T. pallidum required (Riviere, 1989). Riviere et al. (Riviere, 1989) studied the
invasive potential of T. pallidum in vitro and demonstrated the ability of the organism to
penetrate the endothelial cell monolayer.
The route of transmission of syphilis is almost always through sexual contact
however, it can also be acquired congenitally (transmitted transplacentally from an
infected mother to her fetus). It can also be transmitted through blood transfusion.
Primary syphilis is usually characterized by one or more painless chancres of the
skin or mucous membranes at the site of inoculation (Kent, 2008). These lesions are
commonly seen on the genitalia. The changes appear within 3 to 4 weeks after exposure.
These lesions heal spontaneously after 4 to 6 weeks. Induration is the most common sign
and occurs in 47% to 92% of cases (Kent, 2008). Additionally, these lesions have
numerous treponemal organisms and exudates from lesions are highly infectious.
There is no clear distinction between primary and secondary syphilis. However,
secondary syphilis begins about 1 to 2 months after the appearance of the primary
chancre (Kent, 2008). The secondary stage is characterized by rash, mucocutaneous
lesions, and lymphadenopathy (Kent, 2008). A rash can develop over the body and
commonly includes the palms of the hands and the soles of the feet (Euerle, 2011). The
skin rash usually heals in 2 to 12 weeks on its own without scarring. Hypertrophic
papular lesions can occur on the vulva or anus and can easily be confused with human
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papilomavirus infection (Euerle, 2011). The other symptoms of secondary syphilis
manifest as generalized lymphadenopathy, malaise, sore throat, headache, splenomegaly,
and arthralgia (Euerle, 2011). This stage also heals spontaneously even without treatment
in 3 to 12 weeks. Secondary syphilis can last from 2 to 6 weeks. The organisms continue
to disseminate throughout the body via lymphatic and hematogenous spread.
Latent syphilis is referred to as the period after infection when T. pallidum
continues in the body of the infected person without clinical manifestations of disease.
Latent syphilis follows the resolution of secondary syphilis. Latent syphilis is subdivided
into early, late, and unknown categories based on the duration of infection. Latent
syphilis is classified as "early latent" if the infection is known to be less than one year in
duration, "late latent" if the infection is known to be greater than one year in duration, or
"latent syphilis of unknown duration" if the duration of infection is unknown (Euerle,
2011). Common signs and symptoms of latent syphilis include difficulty coordinating
muscle movements, numbness, paralysis, dementia, and gradual blindness (Euerle, 2011).
Tertiary syphilis occurs 15 to 30 years after the initial infection. This stage is
marked by long-term complication of the disease. Three major forms of tertiary syphilis
include late benign (gummatous), cardiovascular syphilis, and neurosyphilis (Singh,
1999). The tertiary stage involves only a gumma formation and cardiovascular
involvement without clinical manifestations of neurosyphilis. Late benign syphilis
typically causes aortitis or gummatous changes of the skin, bone, or viscera.
Cardiovascular syphilis occurs between 10 and 30 years after the initial infection. The
most common manifestaton of cardiovascular syphilis is aortitis, typically involves the
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ascending aorta (Karnath, 2009). Syphilitic aneurysms are the most common
complication of syphilitic aortitis and complicated by aortic insufficiency and
regurgitation (Karnath, 2009). Neurosyphilis is an infection of the central nervous system
invaded by T. pallidum. Neurosyphilis can occur at almost any stage of syphilis. Early
neurosyphilis presents with the involvement of meninges and menigovascular system
after weeks to years of primary infection. Brain and spinal cord involvement usually
indicates late syphilis and occurs years to decades after initial infection (Singh, 1999). As
an untreated complication of progresses, it invades the spinal cord, impairs muscle
function, and causes nerve damage. This condition is referred to as Tabes dorsalis. Tabes
dosalis causes a slow degeneration of the covering of nerve cells and nerve fibers that
relay sensory information to the brain (Singh, 1999). Without medical intervention, it can
lead to mild to severe dementia, paralysis, and blindness. However, even with treatment,
damage to nerve cells and fibers in the spinal cord cannot be reversed. The most common
signs in the tertiary stage include fever, painful and, non-healing skin ulcers, and bone
pain (Euerle, 2011; Karnath, 2009; Kent, 2008)
Congenital syphilis is a multisystem infection caused by T. pallidum and
transmitted placentally to fetus. Transmission to the fetus in pregnancy can occur during
any stage of syphilis. Untreated syphilis during pregnancy is associated with stillbirth,
neonatal death, bone deformities, and neurologic complications (WHO, 2011). Early
signs and symptoms of congenital syphilis are highly variable. Most clinical symptoms
are not seen at birth but show within the 3 months of infant life. Clinical signs and
symptoms of congenital syphilis in infants less than 2 years of age may manifest signs of
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hepatosplenomegaly, rash, codyloma lata, jaundice, hemolytic anemia, hrombocytopenia,
osteochondritis, and pseudoparalysis (Arnold, 2000; Rodriguez-Cerdeira, 2012). Late
congenital syphilis in older children typically manifests after two years of life and causes
gummatous ulcers, periosteal lesions, paresis, tabes, optic atrophy, interstitial keratitis,
sensorineural deafness, and dental deformities (Rodriguez-Cerdeira, 2012).
Yaws is a highly contagious treponematosis. This disease is caused by T. pallidum
subspecies pertenue. Yaws is not spread by sexual contact. Direct skin-to-skin contact is
the main route for transmission. The disease is similar to syphilis and can persist for
many years as a chronic, relapsing infection. Yaws is more common in children with a
peak incidence in those 6 to 10 years of age. Yaws is endemic in the tropical and subtropical areas with hot temperatures, high humidity, and heavy rainfall. The prevalence of
the disease is higher in areas with poor sanitation, overcrowding, and lack of public
health surveillance system (Farnsworth, 2006). The primary stage of the disease begins 2
to 4 weeks after exposure. A small papule known as “mother yaws” develops at the site
of inoculation. A papule gradually develops into a papilloma without treatment. Regional
lymphadenopathy, fever and arthralgias may be seen with the primary stage of yaws
(Farnsworth, 2006). The “mother yaws” may last from several weeks to months and may
last into the secondary yaws. Secondary yaws tends to be more severe and involves in the
skin, palmoplantar and bones. The characteristics of these lesions exhibit large raised
papillomas and papules after a period of latency (about 6 to 16 weeks after the primary
stage). Periostitis, osteitis, polydactylitis, arthralgias, generalized lymphadenopathy,
headaches, and malaise may be associated with the secondary stage of yaws (Farnsworth,
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2006). Five to ten years after infection, 10% of patients enter a tertiary stage of the
disease which is typically characterized by destructive skin lesions and severely
deformed bone and joint lesions (Farnsworth, 2006).
T. pallidum subspecies endemicum is the causative agent of bejel. The infection is
very similar to syphilis but is not sexually transmitted. The primary route of transmission
is through direct contract with infectious lesions on the skin and mucous membranes.
However, the disease can spread by sharing common eating and drinking utensils. The
main reservoir is children 2 to 15 years of age. Bejel is more common in dry, hot climates
in the eastern Mediterranean region and in Saharan West Africa (Falabella, 1994;
Farnsworth, 2006). In the early stage of infection, clinical features are rarely present but
lesions are seen in the mouth, the back of the lips, and on the cheeks. Secondary lesions
may persist in the mouth. The secondary lesions may be papules, macules, or various
other rashes. A generalized lymphadenopathy is common at this stage (Farnsworth,
2006). Tertiary bejel can occur as early as 6 months or as late as several years after initial
clinical manifestations resolve. Gangosa, uveitis, optic atrophy, and chorioretinits may
occur in the late tertiary stage of infection (Falabella, 1994). The organism may infect the
periosteal space, which leads to severe bone deformities.
Pinta is an acute and chronic nonvenereal treponematosis caused by Treponema
carateum. Pinta occurs primarily in remote rural areas of Central and South America.
Brazil, Venezuela, Columbia, Peru, Ecuador, and Mexico have the highest prevalence of
the disease. Pinta is more common in early to late adulthood (Farnsworth, 2006). The
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exact mode of transmission is unknown, but pinta is most likely transmitted by direct skin
or, mucous membrane contact or by fomite contact (Farnsworth, 2006). In the early-stage
disease, a papule appears on the uncovered part of the body. After a few weeks or
months, the papules become small patches. These patches become hypochromic after
several months and may persist for many years. The face and extremities are often the
most affected sites. The secondary stage of pinta occurs between 1 and 12 months after
the primary lesion stage. Many flat, red, scaly, lesions occur either near the primary
lesion, or scattered around the body. The late stage generally develops 2 to 4 years after
the onset of the disease and is characterized by the formation of colorless lesions. Unlike
other endemic treponematosis, pinta has not been implicated in congenital, cardiac, and
neurological abnormalities. Pinta is a rare infectious tropical disease affecting only the
skin (Falabella, 1994; Farnsworth, 2006).
2.5

Laboratory diagnosis of syphilis and prevention
The diagnosis of syphilis remains more challenging than most other infections

due to the inability of the organism to grow in culture. The laboratory diagnosis of
syphilis has primarily relied on the host immunologic response or detection of the
organism from active lesions. The laboratory tests for syphilis are divided into two broad
classes: direct and indirect methods. Direct detection methods include darkfield
microscopy, immunofluorescent staining, and nucleic acid amplication tests (NAATs).
Darkfield microscopy is used for the detection of T. pallidum from lesions or aspirates
collected at the primary stage of syphilis. Histological examination of infected tissues
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using the polymerase chain reaction (PCR) is another example of direct method for the
diagnosis of syphilis. These tests are most useful for the diagnosis of primary, secondary,
and early congenital syphilis (Herremans, 2010). More recently, a number of NAATs
have been used for the detection of T. pallidium in clinical specimens. These methods are
not only useful for diagnosis of primary, secondary, and early congenital syphilis but also
are suitable for monitoring the response to therapy (Ratnam, 2005).
Serological tests, the most common laboratory method, continue to play a
significant role in the diagnosis and management of the disease. Indirect diagnosis is
based on serological tests for the detection of specific T. pallidum antibodies. Serological
tests fall into two classes: nontreponemal tests for screening, and treponemal tests for
confirmation. Nontreponemal assays are widely used for syphilis screening, monitoring
response to treatment, and determining the status of re-infection. Nontreponemal tests
include the Venereal Research Laboratory (VDRL), the rapid plasma regain (RPR), the
toluidine red untreated serum (TRUS), and untreated serum regain (USR) tests. The RPR
and VDRL tests are the most commonly used nontreponemal tests for diagnosis of
syphilis (Larsen, 1995). Known as cardiolipin tests, nontreponemal tests use an antigen,
which contains standardized amounts of cardiolipin, cholesterol-lecithin. These assays
detect both immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies formed by
the host in response to the lipoidal substance released from either damaged host cells or
infected treponemes. However, these nontreponemal tests have lower sensitivity and
specificity (Larsen, 1995). Both RPR and VDRL tests are flocculation tests performed in
a similar manner. The RPR tests uses a stabilized VDRL antigen mixed with charcoal
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particles. When antigen-antibody complexes are formed with a positive serum, black
clumps show up and remain as flocculates or clumps. A high rate of false-positives can
occur in a low-prevalence population of patients. More importantly, false-positive results
are usually due to autoimmune disease, drug addiction, acute viral infections, malaria,
leprosy, mononucleosis, lupus erythematosus, and recent immunizations (Larsen, 1995).
The advantage of nontreponemal tests is that they have a higher correlation with disease
activity. Another advantage of the VDRL test is that it can be performed on cerebrospinal
fluid (CSF) or serum and can be used to diagnose neurosyphilis. However, RPR cannot
be used for testing CSF specimens due to lack of its sensitivity and specificity (Larsen,
1995). The USR test is another nontreponemal test that detects antilipoidal antibodies in
patients with syphilis. A positive USR may indicate a past or present infection with T.
pallidum. The TRUST is a macroscopic nontreponemal flocculation card test for
screening syphilis. It also detects IgM and IgG antibodies to lipoid material from
damaged host cells or cardiolipin released by the treponemes. With a positive test, a red
flocculent forms when the TRUST antigen is mixed with a positive serum on a plasticcoated card. Biological false-positive reactions can occur in patients with autoimmune
disease (Larsen, 1995). A prozone phenomenon can also cause false-negative reactions
with these tests.
The second category of indirect tests is the treponemal tests. All treponemal tests
use the T. pallidum antigen to detect specific anti-treponemal antibodies in serum.
Treponemal assays are most often used to confirm the diagnosis of syphilis in patients
with a reactive RPR or VDRL and rule out biological false positive results from
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nontreponemal assays. Treponemal tests include the T. pallidum particle agglutination
(TP-PA), microhemagglutination assay with T. pallidum antigen (MHA-TP), fluorescent
treponemal antibody-absorption test (FTA-ABS), Western blot test (WB) and enzyme
immunoassay (EIA). The TP-PA assay is a qualitative gelatin particle agglutination assay
used for the detection of specific T. pallidum antibodies in human sera or plasma. The
TP-PA is usually reactive in primary and secondary syphilis. The MHA-TP test is a
passive agglutination test based on the agglutination of gel particles sensitized with T.
pallidum antigens by antibodies found in the patient's serum (Larsen, 1995; OwusuEduse, 2011; Ratnam, 2005). This test is a confirmatory test to replace the (MHA-TP).
The TP-PA test is used to confirm the diagnosis of syphilis in patients with a reactive
RPR or VDRL. One advantage of this test is that the TP-PA test is as sensitive as the
FTA-ABS test in the first stage of syphilis and is just as useful as the RPR in monitoring
response to therapy. The FTA-ABS test is an indirect immunofluorescent antibody test. It
detects antibodies to T. pallidum and can be used to detect syphilis infection at any stage
of the disease. The test is mainly used to rule out biologic false-positives on the
treponemal test reactions and to detect late syphilis in which nontreponemal test result
may be nonreactive. The FTA-ABS test can be performed on either CSF or serum. A
positive result of FTA-ABS-CSF assay can be used to confirm the diagnosis of
neurosyphilis. The FTA-ABS-CSF assay has a sensitivity and specificity for
neurosyphilis of 100% and 99.2%, respectively (LaFond, 2006). The WB test is also
known as immunoblotting. In the treponemal WB, the resolved T. pallidum proteins are
separated by gel-electrophoresis based on their molecular size (Byrne, 1992). These
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proteins are transferred by electrophoresis to a nitrocellulose membrane, which is dried
and cut into strips. These strips are incubated with patient’s serum and antigen-antibody
complexes are seen by adding enzyme-conjugated anti-human globulin followed by
substrate, causing a color change. Lastly, EIAs are used for the detection of treponemal
antibodies in serum. In these tests, the microtiter plate is coated with highly purified
specific T. pallidum antigen. If the T. pallidum-specific antibodies are present in serum,
they bind to and become immobilized by the antigen pre-coated on the microtiter wells.
Only those microtiter wells that contain the T. pallidum IgG/IgM specific antibodies and
horseradish peroxidase (HRPO) conjugate, and show a change in color. A change in color
indicates a positive test. The ELISA tests can use various recombinant antigens to detect
T. pallidum specific IgG, IgM, and IgA antibodies in serum or plasma samples (Larsen,
1995). The intensity of the color change is directly proportional to the amount of
antibody concentration. This makes the test an effective diagnostic tool in all stages of
syphilis with exception of early primary syphilis.

There are 4 major strategies to prevent and control syphilis: 1) education and
counseling of persons at risk; 2) identification of symptomatic and asymptomatic persons
not seeking treatment, 3) effective diagnosis and treatment; and 4) identification,
evaluation, treatment, and counseling of sex partners who are infected with syphilis.
Educating the general public about the serious consequences of syphilis and
reducing the risk of the disease transmission are important strategies in the prevention of
syphilis. For example, condom education is effective in decreasing the transmission of
syphilis and HIV. Condoms have played a significant role in preventing the sexual
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transmission of HIV since the beginning of the epidemic (CDC, 2011). Many
epidemiological studies cited that consistent condom use was found to reduce the
transmission of HIV and STIs by 64% and 42%, respectively (CDC, 2010). According to
the National Institute of Health and the National Institute of Allergy and Infectious
Diseases, syphilis transmission is reduced by 29% with typical use (CDC, 2011)
Behavioral interventions for syphilis prevention are another integral component of
the public education program. The public education program should also focus on “safer
sex practices” and risk reduction strategies and risk behaviors. Counseling is an essential
part of primary prevention strategies for reducing the transmission of syphilis. For
example, trained counselors can discuss an individual’s risky behaviors and provide the
necessary information on how to reduce their risk for contracting syphilis.
According to the United States Preventive Services Task Force recommendation
published in 1996, all pregnant women and persons at high risk for infection should be
screened by routine serological testing for syphilis (Calonge, 2004). There is compelling
evidence that screening for syphilis reduces morbidity or morality, the incidence of
congenital syphilis in newborns, and disease transmission. A study evaluating the impact
of serological screening testing in pregnant women revealed a decrease in the proportion
of infants with clinical signs and symptoms syphilis, suggesting early detection and
intervention can prevent the development of clinical disease with appropriate
interventions (Calonge, 2004). Syphilis is a highly prevalent infection among MSM and
transgender people, particularly among MSM living with HIV (WHO, 2010). An early
diagnosis of syphilis in MSM and other high “risk group” would provide timely treatment

20

and benefit the individual and partners. Targeting the screening of the ‘risk group” is
useful in the control of transmission of the disease.
There are many effective ways to prevent, diagnose, and treat syphilis. Prompt
diagnosis and effective treatment of syphilis are necessary to avoid the serious
complications and the spread of the disease. Treatment based on presumptive diagnosis
of syphilis should be inexpensive, simple, safe, and effective. Targeting and treating the
highly “risk group” have been very useful. For example, selective mass treatment of
commercial sex workers prevented the spread of ongoing syphilis epidemic in Fresno,
California in 1977 (Singh, 1999). WHO also adopted the same strategy to eradicate yaws.
The effective use of this mass treatment strategy markedly lowered the prevalence of the
disease in certain communities.
Prompt notification and treatment of sex partners after diagnosis of syphilis are
essential to reduce the spread of disease and the risk of reinfection. This program can be
effective if interventions focus on the importance of notification, improvement of
communication skills, development of contact tracing programs and expedient partner
therapy. The partner notification process involves a series of interrelated activities such
as, interviewing the infected patient to obtain a complete list of exposed sex partners and
locating these individuals in the community. Examination of partner notification data
could provide valuable information regarding the social networks in a community and
capture opportunities for targeted interventions. This allows for assistance in identifying
and treating potentially infected sexual partners. All sexual partners need to be notified
about an infection so they can be tested and, if necessary, treated. Partner services should
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be carefully monitored and evaluated for completeness, timeliness, effectiveness, and
cost-effectiveness.
Finally, penicillin is the drug of choice for treating all stages of syphilis according
to the 2010 CDC STD Treatment Guidelines (MMWR, 2010). Additionally, penicillin
remains the mainstay of treatment for neurosyphilis, congenital syphilis, or syphilis
during pregnancy (MMWR, 2010). Alternate therapeutic agents are also available for
treating penicillin-allergic patients with primary and secondary syphilis. Tetracycline,
erythromycin, and ceftriaxone are effective for treating patients allergic to penicillin. The
CDC 2010 STD Treatment Guidelines reports the effectiveness of azithromycin in
treating early syphilis (CDC, 2010). However, there are some cases of treatment failure
due to azithromycin-resistant mutations in T pallidum in several areas of the United
States (MMWR, 2010). Additional studies are needed to confirm the efficacy of
azithromycin before this treatment can be routinely used for treating syphilis. Despite
efforts to develop a safe and effective syphilis vaccine, there is currently no vaccine to
prevent syphilis. To this day, penicillin continues to be the drug of choice for the
treatment of all stages of syphilis.
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Chapter III

METHODOLOGY

The study evaluated the sensitivity and specificity of a T. pallidum DBS method
for serologic diagnosis of syphilis in comparison to serum results.

3.1

Study population and enrollment
A total of 200 serum and DBS specimens collected from patients at the Los Angeles

Municipal Sexually Transmitted Disease Clinics. Eligible subjects were those ≥20 years old

with symptoms of a chancre on the genitals, rectum or mouth, swelling of the lymph
nodes in the groin, fever, headache, achiness, loss of appetite, rash, painful non-healing
skin ulcers and bone pain. Written informed consent was obtained from all study
subjects, and signs and symptoms of syphilis, and medication history were assessed. DBS
and serum specimens were collected from patients undergoing syphilis evaluation and
testing in the STI clinics. These samples were sent to the Syphilis Diagnostics Lab,
Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia testing. Samples
were blindly evaluated by the DBS and the TREP- SURETM EIA methods for the
detection of anti-treponemal IgG- and IgM-class antibodies.
3. 2

Data sources and procedure
A total of 200 DBS and serum specimens were collected from participants in the

study. The study was conducted during a 52 week period in September 2011 to
September 2012. TREP- SURETM was performed on serum at baseline (gold standard)
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and was compared with DBS results. TREP- SURETM is a qualitative EIA for the in vitro
diagnostic detection of T. pallidum antibodies in human serum or plasma. This kit is
commercially available and designed as a confirmatory test for T. pallidum. In this assay,
the specific recombinant treponemal antigens are pre-coated on the microtiter plate wells.
Patient sera (100 µl undiluted) and controls were added to the wells and incubated for 60
minutes at 37°C. The contents in the wells were discarded and washed 4 times with 300
µL per well of Wash Buffer Working Solution. Then, enzyme conjugated (100 µl)
antigens were added to all wells and incubated for 30 minutes at 37°C. Again, the
contents in the wells were discarded and washed 4 times with 300µL per well of Wash
Buffer Working Solution after incubation. Tetramethylbenzidine (TMB) substrate
solution (100 µl) was added to all wells and incubated the plate for15 (±2) minutes at
37°C, protected from light. Finally, Stop Solution (100 µl) was added to all wells. The
plate microtiter plate wells were read within15 minutes with optical density at 450 nm
and results were calculated. If specific anti-treponemal antibodies were present in the
patient’s serum, T. pallidum antibodies specifically were bound to the immunized
antigens on the wells. The antigen-antibody complexes reacted with HRPO conjugated
treponemal antigen. After a second washing step which removes the unbound conjugates,
a color reaction takes place on the well as a result of addition of the peroxidase substrate,
TMB. A color change is measured after adding stop solution. The amount of antibody
present in the patient’s serum is directly proportional to the color intensity in the
microtiter wells. Results are expressed as an Optical Density (OD). If OD is greater than
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1.2 it is considered positive and less than 0.8 as negative. If OD is between 0.8 and 1.1, it
is considered an equivocal result. The complete assay takes about 3 hours.
For the DBS testing method (TREP-SPOTTM DBS) two 6.0 - 6.2 mm blood discs
were punched from patient’s dried blood spot card using a puncher and DBS discs were
placed in 300 µl elution buffer, placed on a shaker on low speed and incubated for
overnight at 4°C. The contents in the wells (100 µl) were transferred to the testing plate
and 100 µl elution buffer was added to all wells in the plate and incubated for 30 minutes
at 37°C. The contents in the wells were discarded and washed five times with 300µL per
well of Wash Buffer Working Solution. Then, enzyme conjugated (100 µl) antigens were
added to all wells and incubated for 30 minutes at room temperature (RT). Again, the
contents in the wells were discarded and washed 4 times with 300µL per well of Wash
Buffer Working Solution after incubation. TMB substrate solution (100 µl) was added to
all wells and the plate was incubated for 10 minutes at RT. Finally, Stop Solution (100
µl) was added to all wells. The microtiter plate wells were read within 15 minutes with
optical density at 450 nm and calculated results as same as the TREP- SURETM method.

3.3

Data analysis

To evaluate performance characteristics, the following values were used: true positive
(TP), false positive (FP), true negative (TN), and false negative (FN). A true positive is
when the patient has the disease and the test is positive by the gold standard. Sensitivity,
specificity, positive predictive value (PPV), negative predictive value (NPV), and
efficiency (E) were calculated. The following formulas were used to calculate test
indices:
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1) sensitivity = [TP/(TP + FN)] × 100;
2) specificity = [TN/(TN + FP)] × 100;
3) PPV = [TP/(TP + FP)] x 100;
4) NPV = [TN/(TN + FN)] x 100;
5) E = [(TP + TN)/(TP + FP + FN + TN)] x 100.
All statistical calculations were performed using the Microsoft Office Excel 2010 and
Clinical Calculator 1 - VassarStats. Statistical Computation Web. Kappa coefficients
were calculated as a measure of agreement using the Chest X-ray Computation Web
(http://www.graphpad.com/quickcalcs/kappa1/). The agreement of the results by kappa
(κ) values is categorized as near perfect (0.81 to 1.0), substantial (0.61 to 0.8), moderate
(0.41to 0.6), fair (0.21 to 0.4), slight (0 to 0.2), or poor (<0). Correlation coefficients (r2)
measure the strength of association between two values. The value of a correlation
coefficient ranges between -1 and 1. The greater the absolute value of a correlation
coefficient, the stronger the linear relationship. The strongest linear relationship is shown
by a correlation coefficient of -1 or 1. The weakest linear relationship is shown by a
correlation coefficient equal to 0.
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Chapter IV

RESULTS
The study was designed to determine the sensitivity and specificity of a T.
pallidum DBS method for serologic diagnosis of syphilis in comparison to serum results,
by answering the following 3 questions:
1. Does a T. pallidum dried blood spot method provide high sensitivity and
specificity for the diagnosis and confirmation of syphilis?
2. Can a T. pallidum dried blood spot method be used for the diagnosis and
confirmation of syphilis?
3. Does a T. pallidum dried blood spot method offer an easy and convenient
way to collect and transport blood samples for the diagnosis and
confirmation of syphilis?
4.1

The performance characteristics of DBS method
A total of 200 serum and DBS specimens collected from patients at the Los Angeles

Municipal Sexually Transmitted Disease Clinics were tested by the DBS and EIA methods. In
all, the 100 specimens found to be reactive by the TREP-SURE

TM

EIA were tested by the

TREP-SPOTTM DBS EIA. As shown in Figure 1, 83 were found to be reactive and 17
were found to be nonreactive by the TREP-SPOTTM DBS EIA. As shown in Table 1,
sensitivity, specificity, positive predictive value, negative predictive value, efficiency were
calculated using the formula below in Table 1.
The sensitivity of the DBS method was 83% (95% CI, 73.89 - 89.50) and specificity was
100% (95% CI, 95.39 - 100)). The positive predictive value and negative predictive values were
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100% (95% CI, 94.48 – 100) and 85% (95% CI , 77.43 - 91.0), respectively. The efficiency of
the DBS method was 91.5%. The kappa (κ) value for the agreement between the DBS method
and EIA assay was 0.83 (95% CI, 0.754 - 0.906). The correlation coefficient (r 2) between the
anti-treponemal antibody assay results obtained from DBS and serum samples is shown in Figure
1, demonstrating, r2 = 0.94. Comparison of these results demonstrated a statistically significant
positive correlation.

4.2

DBS method for the diagnosis of syphilis
These results indicate that DBS method can be used to detect anti-treponemal

antibody in DBS samples. The DBS method demonstrated less sensitive (83% sensitivity)
than the TREP-SURETM EIA assay for the diagnosis of syphilis, but was significantly
specific (100% specificity). The DBS method is an alternative to the use of combined
VDRL and RPR tests for screening for syphilis. If the DBS method is used for screening
alternative treponemal test, TPHA should be used for confirmatory testing. The method is
particularly useful to surveillance in countries with limited resources settings.

Table 1. Comparison of DBS And Serum Sample

DBS
SAMPLE

POSTIVE
NEGATIVE
TOTAL

SERUM
SAMPLE
POSTIVE
TP 83
FN 17
100

NEGATIVE
FP 0
TN 100
100

TOTAL
83
117
200
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Table 2. Sensitivity, Specificity, Positive Predictive Value, Negative Predictive
Value, Efficiency, Kappa, and Correlation Coefficient On 200 Dried Blood Samples
Against Gold Standard Of The TREP-SURETM EIA In Serum

Estimated
Value
Sensitivity
Specificity
Positive predictive value

0.83
1
1

Negative predictive value
Efficiency
Kappa
Correlation coefficient

0.854701
0.915
0.83
0.94

95% confidence Interval
Lower Limit
Upper
Limit
0.73891
0.89506
0.95389
1
0.94487
1
0.77473
0.9106
0.754

0.906
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Figure 1. Correlation DBS And Serum Index Values
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Collection and transport of DBS specimens
The T. pallidum dried blood spot method offers an easy and convenient way to collect

and transport blood samples for the diagnosis of syphilis. Sample ccollection using the
DBS technique is simple as shown Figure 2. As shown in Figure 3, dried blood spots can
be used as an easy and inexpensive means for the collection and storage of peripheral
blood specimens from infants, children and adults in settings where collection and
storage of plasma is not optimal. No special handling is needed. DBS sampling would be
a good choice to be used as a screening tool for the screening of syphilis. Some risks
associated with transport and shipping are minimized because DBS cannot leak or be
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broken in transit. Another advantage of DBS samples over routine serum/plasma samples
is that only a small quality of blood, typically 50 µl, is required to make one dried blood
spot. DBS specimens are easy to collect and store, and can be a convenient alternative to
plasma or serum in resources-limited settings.
Figure 2. Dried Blood Spot Collection Card
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Figure 3. A Collected Blood Sample

4.4

Summary of results
To summarize, we found that the sensitivity of the DBS method was 83% ((95%, CI, 73.89 -

89.50) and specificity was 100% (95% CI, 95.39 - 100). The positive predictive value and
negative predictive values were 100% (95% CI, 94.48 -100) and 85% (95% CI, 77.43 - 91.0),
respectively. The efficiency of the DBS method was 91.5%. The kappa value for the agreement
between the DBS method and EIA assay was 0.83 (95% CI, 0.745 - 0.906). The correlation
coefficient (r2) between the anti-treponemal antibody assay results obtained from DBS and serum
samples was 0.94.
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Chapter V
DISCUSSION AND CONCLUSION
5.1

Discussion
We evaluated the sensitivity, specificity, positive predictive value, negative

predictive value, efficiency (overall agreement), kappa and correlation coefficient of the
TREP-SPOTTM DBS assay, comparing it with the most commonly used reference test for
the diagnosis of syphilis. The sensitivity, specificity, positive predictive value, negative
predictive value, and efficiency (overall agreement) were 83%, 100%, 100%, 85%, and
91.5%, respectively, when tested on 200 DBS and serum specimens. The ideal test is one
that has very high sensitivity and specificity, so that most true cases are identified and
most non-cases are excluded. The results obtained showed lower sensitivity and high
specificity of the TREP-SPOTTM DBS EIA when compared with the TREP-SURETM
EIA. As shown in Table 1, a total of 200 specimens tested, 83 were found to be reactive
by the TREP-SPOTTM DBS EIA and 100 were found to be nonreactive by the TREPSURETM EIA. Of the 100 TREP-SURETM EIA-reactive specimens, 17 were nonreactive
by the TREP-SPOTTM DBS EIA. These false negative results may be due to a very small
concentration of antitreponemal antibodies present in the DBS samples.
The main factors influencing the low sensitivity (83%) could be due to the
following three reasons: the amount of blood, dilution and cut-off values used. The
amount of blood used for the preparation of the DBS samples was very minute using
aliquots of only 5 μl of whole blood. Blood from the DBS punched disc was eluted with
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100 μl of eluent buffer, further diluting the sample to 1:20 dilution. Therefore, the assay
titers obtained from DBS samples were shown to be lower than the titers from the serum
samples. Lastly, the same cut-off values (index values) used for the TREP-SURETM EIA
was used for the DBS samples, when they should not be.
In our example, the TREP-SPOTTM DBS EIA shows very high specificity (100%)
for the detection of anti-treponemal antibodies. This demonstrates that the DBS sample
method is unlikely to yield a false positive result. The specificity is the proportion of
individuals without the disease who are correctly identified by the test as not having it.
The positive predictive and negative predictive values were found to be 100% and 84%,
respectively. When disease prevalence is relatively low, the positive predictive value
(PPV) is low and false-positive test results are more likely. By contrast, when disease
prevalence is low, the negative predictive value (NPV) is high, and negative results are
more likely to be true. Sensitivity and specificity, the PPV and NPV will change with the
prevalence of a disease. For rare diseases, the PPV will always be low or lower, even
when a test is near perfect in terms of sensitivity and specificity.
The TREP-SPOTTM DBS showed efficiency (91%) with the TREP-SURETM EIA
for testing anti-treponemal antibodies. A high efficiency was measured between these
two assays using DBS and serum specimens. A kappa value of 0.83 (95% CI, 0.754 0.906) was found for the agreement between the TREP-SPOTTM DBS and the TREPSURETM, showing good agreement between these two tests. The TREP-SPOTTM DBS
EIA showed near perfect correlation (R2 = 0.91).
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In summary, the findings indicate that dried blood spots are a feasible alternative
to serum for serologic diagnosis of syphilis. DBS samples compared favorably to the
results of the TREP-SURETM EIA, with an overall concordance of 91%. Dried blood
spots are a convenient alternative to serum/plasma and are suitable for blood sampling in
the primary health care setting. Studies shown on DBS samples in resource-limited
settings have proven the usefulness and accuracy of these samples for the serological and
molecular diagnosis of HIV and Hepatitis infections (Lee, 2011; Patton, 2006).

5.2

Study Limitations

This study has a number of limitations. First, we did not use a large study sample
size. The small sample sizes (200 specimens) possibly reduced the power of the study to
detect differences between the methods. The influence of sample size on the power of a
test is critical. The larger the sample size in the future study will assure the greater
statistical significance between the TREP-SURETM EIA and the TREP-SPOTTM DBS
EIA. Second, all patients enrolled in the study did not provide clinical information
(underlying diseases, disorders, or conditions) that are likely to have a large bearing on
the ability of the test to reliably rule out the possibly of false positive and negative
results. It is well documented that Tuberculosis, Lyme disease, human immune
deficiency virus (HIV) infections, and leptospirosis can cause biological false positives in
syphilis (Ratnam, 2005). In contract, the latent syphilis and HIV co-infected with
Tuberculosis can also cause biological false negatives in patients with syphilis (Ratnam,
2005). It is possible that seventeen false negative (17) results from the DBS samples
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could have been attributed to pre-exiting or underlying medical conditions. It is also
possible that false negative results might occasionally occur for another reason. Because
all test results were not evaluated in concert with a clinical diagnosis and history due to
unavailability of clinical diagnosis and history. Lastly, we did not use another
confirmatory test in this study. DBS samples giving discrepant treponemal test results (17
false negatives) need to be further tested by another confirmatory method using either the
FTA-ABS or PCR analysis.

5.3

Recommendations

Based on our findings, the study clearly showed DBS underestimated positive
results mainly at low OD level, which could be due to the low blood volume in the spot.
In particular, research should focus on further optimization of the assay using different
cut-off values for the validation of the positivity and negativity in DBS samples because
the small amount blood in the DBS specimens leads to lower assays titer.
The TREP - SPOTTM DBS EIA may be suitable for the detection of antibodies T.
pallidum and warrant further evaluation using a larger sample size in the study. A higher
sample size gives more accurate results. Sample size is important primarily because of its
effect on statistical power. Statistical power is the probability that a statistical test will
indicate a significant difference when there truly is one. Attention to sample size will
result in a more meaningful study, with results more representative of the population,
which the research is geralizing. A high sample size of the study should be considered
early in the planning phase of the study.
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5.4.

CONCLUSION
The use of dried blood spots is often the best sampling option for the detection of

anti-treponemal antibodies for the diagnosis of syphilis in limited resource settings. The
study findings indicate that DBS are a feasible alternative to serum/plasma for serological
confirmation of syphilis. The detection anti-treponemal antibodies compared favorably to
the results of serum-based assay (TREP-SURETM) EIA, with a specificity of 100% and
an overall concordance of 91.5%.
Even though the results from DBS samples showed a lower relative sensitivity
(83%), dried blood spots are technically easier to obtain and are suitable blood samples
for primary health care centers. DBS can be collected from a heel, toe, and finger prick or
prepared from venous blood. The relative ease of sample collection, transport, and
storage are significant benefits.
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